Biologics in Practice: Unique Opportunity for Allergist Expertise (MOC)

You can earn up to 2.0 AMA PRA Category 1 Credit(s)™. This activity has also been designated by the ABAI for 2.0 MOC Part II Self-Assessment credits. Cost: $40 $20 for College Members, $60 $30 for non-members.

These presentations will review: 1) recent advances in our understanding of immune mechaninisms of asthma including roles of epithelial cells and epithelial cell derived cytokines and novel immune cell types including ELC2, ELC3, iNKT cells, gd cells, and Th17 cells; 2) the therapeutic potential of immune response modifiers (IRMs); discussion of strategies to optimize treatment with IRMs including the role of personalized medicine; and discuss patient-specific features that can influence IRMs' therapeutic benefits; and 3) presentations and management of hypersensitivity reactions to biologics.

 

Release Date: 12/15/2015
Expiration Date: 12/14/2018

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

• Discuss phenotypes and endotypes in the context of the patient with severe asthma 
• Describe the relative advantages and disadvantages associated with various asthma pharmacotherapies, particularly biologics 
• Discuss the side effect profiles of the various new therapies and how to go about handling such complications

Additional information
Disclosure: 

Rohit K. Katial, MD, FACAAI -- Consultant/Advisor: AstraZeneca, GlaxoSmithKline, Meda, Teva; Speaker: GlaxoSmithKline, Meda

James L. Sublett, MD, FACAAI -- Consultant/Advisor: Boston Scientific, Greer; Speaker: Genentech, GlaxoSmithKline, Meda, Merck, Sunovion, Teva; Supported/Contracted Research: Array BioPharma, AstraZeneca, Boehringer Ingelheim, Forest, Mylan, Sanofi

Larry Borish, MD, FACAAI -- Consultant/Advisor: Allakos, Knopp, Novartis, PluriStem

Thomas B. Casale, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Genentech, Novartis, Sanofi, Teva

David A. Khan, MD, FACAAI -- Speaker: Baxter, Genentech

Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Attendance
  • 2.00 MOC
Course opens: 
12/15/2015
Course expires: 
12/14/2018
Cost:
$30.00
Rating: 
0

Rohit K. Katial, MD, FACAAI

James L. Sublett, MD, FACAAI

Larry Borish, MD, FACAAI

Thomas B. Casale, MD, FACAAI

David A. Khan, MD, FACAAI

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Attendance
  • 2.00 MOC

Accreditation Period

Course opens: 
12/15/2015
Course expires: 
12/14/2018

Price

Cost:
$30.00
Please login or create an account to take this course.